Published in Gene Therapy Weekly, March 23rd, 1998
DNA-based immunization strategies offer an attractive alternative to protein- or peptide-based approaches because they do not require prior knowledge of the patient HLA haplotype or specific T cell epitopes.
Thomas Tuting and colleagues from several institutions evaluated the potential of DNA vaccination for immunotherapy of malignant melanoma in an in vitro vaccine model using dendritic cells (DC) ("Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.